Dr. Luke on Adjuvant Therapies in Development for Melanoma

Video

In Partnership With:

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive® State of the Science Summit on Melanoma and Immuno-Oncology.

There are many therapies currently being explored in ongoing trials, Luke explains. There have not yet been read-outs on any of these studies; however, results are expected soon on the comparison of PD-1 inhibitors with nivolumab (Opdivo) or pembrolizumab (Keytruda) versus CTLA-4 inhibitors in the adjuvant setting.

Additionally, researchers expect that such trials will be positive for PD-1 agents as they are known to have a better safety profile than CTLA-4 inhibitors, such as ipilimumab (Yervoy).

Moreover, there is another trial of the adjuvant combination of PD-1 plus CTLA-4 inhibitors; this is likely to be very toxic, Luke cautions. Finally, BRAF inhibitors are also being investigated as adjuvant treatments.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD